Is Sol-Gel Technologies a Buy?
Most investors have probably never heard of Sol-Gel Technologies (NASDAQ: SLGL). That wouldn't be too surprising. It's a small Israeli-based dermatology company with a pretty limited pipeline. The pharma stock tumbled in 2018 to drag the company's market valuation well below $100 million and likely off the radar of most investors.
But the narrative may have changed. Sol-Gel delivered positive late-stage results for two of its drug candidates in the second half of 2019. That nudged the company's market valuation above $300 million at the start of this year, although it has cooled off a little. Should investors take this small-cap stock seriously as it prepares to file two new drug applications (NDA) to the Food and Drug Administration in 2020?
Image source: Getty Images
Source Fool.com
